International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 10-No.4 (2024) pp. 2771-2780
http://www.ijcesen.com

ISSN: 2149-9144

Research Article

Role of Pharmacists in Pharmacovigilance and Adverse Drug Reaction Reporting

Mohammed Dhahi D Aljohani[1]*, Bodor Alaree Alenezi[2], Mona Maashi Aldhiyahi Alruwaili[3], Reem Olayan Alribi Alruwaili[4], Hassan Maneeallah Naji Alsaadi[5], Yazeed Krayem Hassan Alquairi[6], Maryam Hejje M Alanazi[7], Fahad Obaidullah M Alrashedi[8], Fahad Zamil Fahad Aljaloud[9], Abdulkarim Bayiq G Alshammari[10], Abdullah Mayoud Awad Al-Siyali[11]

[1]Pharmacist, Madinah Health Cluster, Madinah, Madinah Region, Saudi Arabia
* **Corresponding Author Email:** Maljehani@moh.gov.sa- **ORCID:** 0000-0002-5247-7800

[2]Pharmacist, Security Forces Hospital, Riyadh, Riyadh Region, Saudi Arabia
Email: Ph.bodor@gmail.com- **ORCID:** 0000-0002-5247-7050

[3]Pharmacy Technician, Directorate of Health Affairs in the Northern Borders Region, Arar, Northern Borders Region, Saudi Arabia
Email: Momaalruwaili@moh.gov.sa - **ORCID:** 0000-0002-5247-7150

[4]Pharmacy Technician, North Medical Tower, Northern Borders Health Cluster, Arar, Northern Borders Region, Saudi Arabia
Email: reemoa@moh.gov.sa - **ORCID:** 0000-0002-5247-7250

[5]Pharmacy Assistant, Abyar Al-Mashi Primary Health Care Center, Madinah Health Cluster, Madinah, Madinah Region, Saudi Arabia
Email: hamaalsaadi@moh.gov.sa - **ORCID:** 0000-0002-5247-7350

[6]Pharmacy Technician, King Salman Specialist Hospital, Hail Health Cluster, Hail, Hail Region, Saudi Arabia
Email: Yalqaeri@moh.com - **ORCID:** 0000-0002-5247-7450

[7]Pharmacy Technician, Maternity and Children Hospital, Northern Borders Health Cluster, Arar, Northern Borders Region, Saudi Arabia
Email: Malanazi263@moh.gov.sa - **ORCID:** 0000-0002-5247-7550

[8]Pharmacy Technician, King Fahad Specialist Hospital, Qassim Health Cluster, Buraydah, Qassim Region, Saudi Arabia,
Email: falrshedi@moh.gov.sa- **ORCID:** 0000-0002-5247-7650

[9]Pharmacy Technician, Al-Shinan Hospital, Hail Health Cluster, Al-Shinan, Hail Region, Saudi Arabia,
Email: fahdjaloud@gmail.com - **ORCID:** 0000-0002-5247-7750

[10]Pharmacy Technician, Maternity and Children Hospital, Hail Health Cluster, Hail, Hail Region, Saudi Arabia,
Email: abokrm128@yahoo.com- **ORCID:** 0000-0002-5247-7850

[11]Pharmacy Technician, Children's Hospital, Taif Health Cluster, Taif, Makkah Region, Saudi Arabia
Email: aalsayyali@moh.gov.sa- **ORCID:** 0000-0002-5247-7950

Article Info:

DOI: 10.22399/ijcesen.4240
Received : 01 August 2024
Accepted : 30 August 2024

Keywords

Pharmacists,
pharmacovigilance,
adverse drug reactions,
ADR reporting,
medication safety,
patient consultations

Abstract:

Pharmacists play a crucial role in pharmacovigilance, which involves the monitoring, assessment, and prevention of adverse drug reactions (ADRs). As accessible healthcare professionals, pharmacists are often the first point of contact for patients experiencing medication-related issues. They are trained to recognize the signs of ADRs and to understand the complex interactions that can occur with various medications. By actively engaging with patients during consultations, pharmacists can gather valuable information about drug therapy and identify potential safety concerns. Their expertise not only aids in the immediate management of ADRs but also contributes to the broader system of pharmacovigilance by reporting these incidents to regulatory authorities, which can lead to safer medication practices and greater public health outcomes. In addition to their role in identifying and managing ADRs, pharmacists also serve as educational resources for both patients and healthcare providers. They can provide vital

information about drug safety, proper usage, and potential side effects, thus empowering patients to take an active role in their health care. Pharmacists can also influence prescribing practices by providing feedback to prescribers about reported ADRs and offering recommendations for alternative therapies when necessary. By maintaining accurate records of ADRs through systematic reporting pathways, pharmacists significantly contribute to database systems that track medication safety and effectiveness, ultimately enhancing drug surveillance and aiding in informed clinical decision-making.

1. Introduction

The discovery and development of modern pharmaceuticals represent one of the most significant achievements in medical science, offering unprecedented capabilities to treat, manage, and prevent disease. However, the power of any active drug is inherently dualistic, carrying the potential for both therapeutic benefit and unintended harm. This reality underpins the critical discipline of pharmacovigilance, defined by the World Health Organization (WHO) as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem" [1].

The scale of the problem is substantial. Adverse Drug Reactions (ADRs) represent a major public health concern, contributing significantly to global morbidity, mortality, and healthcare costs. A seminal study published in the *Journal of the American Medical Association* estimated that serious ADRs account for over 2 million cases and 100,000 deaths annually in the United States alone, making them a leading cause of death ahead of diseases like diabetes and pneumonia [2]. The economic burden is equally staggering, with the cost of drug-related morbidity and mortality exceeding $500 billion annually in the U.S., a figure that reflects emergency department visits, hospital admissions, and lost productivity [3]. Globally, the WHO estimates that ADRs rank among the top ten leading causes of death, highlighting a pervasive challenge that transcends national healthcare systems [4]. These statistics underscore the urgent and continuous need for robust pharmacovigilance systems to identify, evaluate, and minimize the risks associated with pharmaceutical products throughout their lifecycle.

The historical foundation of modern pharmacovigilance was tragically laid by disasters such as the thalidomide catastrophe in the late 1950s and early 1960s, which led to the birth of formal drug safety monitoring systems. In response, many countries established national pharmacovigilance centers and implemented spontaneous reporting systems (SRS), which rely on healthcare professionals and patients to voluntarily report suspected ADRs. Despite their proven value, these systems are plagued by significant under-reporting, with estimates suggesting that less than 10% of all serious ADRs are ever reported to regulatory authorities [5]. The reasons for this are multifactorial, including lack of time, uncertainty about the causal relationship between the drug and the reaction, complacency (only reporting serious or unusual reactions), and a lack of awareness or feedback. This profound under-reporting creates a dangerous knowledge gap, delaying regulatory action and leaving future patients vulnerable to preventable harm.

Evidence increasingly demonstrates that the active involvement of pharmacists in pharmacovigilance activities significantly strengthens the entire system. A systematic review by Abdel-Latif and Abdel-Wahab found that educational interventions and active participation of pharmacists in the hospital setting led to a significant increase in the quantity and quality of ADR reports, thereby enhancing the detection of previously unknown drug safety signals [6]. Furthermore, studies have shown that pharmacist-led medication reconciliation and review during hospital admission and discharge can identify and prevent numerous potential ADRs, improving patient outcomes and reducing readmission rates [7]. In the ambulatory care setting, clinical pharmacists working in primary care clinics have been instrumental in monitoring patients on high-risk medications, such as anticoagulants and biologics, ensuring that any adverse events are promptly identified and managed [8].

Beyond spontaneous reporting, pharmacists contribute to more advanced forms of pharmacovigilance. They are key players in active surveillance initiatives, such as those conducted within hospital-based intensive monitoring programs. They also provide critical data for pharmacoepidemiological studies that investigate drug safety issues in large populations. Their expertise is vital in assessing causality, using standardized algorithms like the Naranjo scale, to determine the likelihood that a drug caused a specific adverse event [9]. This professional judgment adds a layer of quality and reliability to the reports submitted to national databases.

The global COVID-19 pandemic further highlighted and expanded the role of pharmacists in pharmacovigilance. With the rapid deployment of

novel vaccines and therapeutics, pharmacists were on the front lines, administering millions of doses and actively monitoring for any potential side effects. They played a crucial role in reporting events to systems like VAERS in the U.S. and V-safe, thereby contributing real-world data that was essential for confirming the safety profile of these new medical products and maintaining public confidence [10].

Despite this critical role, several barriers hinder pharmacists from fully realizing their potential in pharmacovigilance. These include a lack of dedicated time, insufficient training in ADR reporting processes, ambiguity regarding professional responsibilities, and, in some settings, the absence of a supportive institutional culture that prioritizes medication safety [11]. To overcome these challenges, there is a growing call to integrate pharmacovigilance more deeply into undergraduate and postgraduate pharmacy curricula and to establish clear protocols and incentives for reporting within healthcare institutions [12].

2. The Pharmacovigilance Landscape:

The inherent limitations of pre-approval clinical trials are multifaceted and create an unavoidable "safety deficit" at the time of a drug's launch. Firstly, these trials involve a relatively small number of participants, typically ranging from a few hundred to a few thousand. This sample size is statistically powerful enough to detect frequent adverse reactions but is often insufficient to identify rare yet serious events that may occur at rates of 1 in 1,000 or 1 in 10,000. For instance, a serious adverse reaction with an incidence of 1 in 5,000 would be highly unlikely to be observed in a trial of 3,000 patients [13]. Secondly, the patient population in clinical trials is highly selective. Participants are often carefully screened to exclude individuals with significant comorbidities, the elderly, pregnant women, and children. This homogeneity fails to represent the diverse, complex, and often multimorbid patient population that will eventually use the drug, where polypharmacy is common and drug-disease or drug-drug interactions can precipitate unforeseen ADRs.

Furthermore, the duration of clinical trials is finite, usually lasting from a few months to a few years. This is adequate for assessing the safety of short-term treatments but is wholly inadequate for identifying adverse effects associated with long-term or chronic use. Effects such as carcinogenicity, certain organ toxicities that develop slowly, or issues related to dependency may only become apparent after years of widespread use. Finally, the controlled environment of a clinical trial, with its strict protocols and close monitoring, is far removed from the realities of clinical practice. In the real world, patients may not adhere perfectly to dosing schedules, may use over-the-counter products concurrently, and may have lifestyle factors (like diet and alcohol consumption) that can alter a drug's effects. These limitations are not a failure of clinical trial design but rather a reflection of its practical and ethical constraints. Therefore, post-marketing surveillance is not an optional add-on but an indispensable component of the drug safety lifecycle [7].

The consequences of this safety knowledge gap are profound, as Adverse Drug Reactions (ADRs) represent a major, and often underestimated, global public health burden. A landmark meta-analysis of prospective studies from U.S. hospitals, published in the *Journal of the American Medical Association*, provided a startling quantification of this problem. The study concluded that serious ADRs accounted for over 2.2 million cases annually among hospitalized patients in the United States, and were responsible for over 106,000 fatal outcomes, making them between the fourth and sixth leading cause of death in the nation [14]. This places fatal ADRs ahead of other significant public health threats such as diabetes mellitus, pneumonia, and motor vehicle accidents. The burden extends beyond mortality to significant morbidity, leading to prolonged hospital stays, permanent disability, and a substantial reduction in quality of life for millions of patients worldwide.

The economic impact of ADRs is equally staggering, placing an immense and preventable strain on healthcare systems. A comprehensive analysis by Watanabe et al. (2018) estimated the annual cost of drug-related morbidity and mortality resulting from non-optimized medication therapy in the U.S. to be a staggering $528.4 billion, equivalent to approximately 16% of total U.S. healthcare expenditures [15]. These costs are not confined to direct medical expenses, such as emergency department visits, hospital admissions, and additional treatments, but also include indirect costs like lost productivity and long-term disability. In the United Kingdom, a study by Pirmohamed et al. found that ADRs were responsible for 4% of all hospital bed capacity and directly cost the National Health Service (NHS) approximately £466 million per year [16]. These figures underscore that investing in robust pharmacovigilance is not only a clinical and ethical imperative but also an economic one, where proactive safety monitoring can lead to substantial cost savings by preventing adverse outcomes.The history of medicine is punctuated by tragic drug safety disasters that have served as

catalysts for the development of modern pharmacovigilance systems. The most poignant example is the thalidomide catastrophe of the late 1950s and early 1960s. Marketed as a safe sedative and treatment for morning sickness in pregnant women, thalidomide was found to cause severe birth defects, notably phocomelia, in thousands of children worldwide [17]. This event starkly revealed the teratogenic potential of drugs and the vulnerability of the fetus, a population almost universally excluded from clinical trials. The public outcry and lessons learned from thalidomide directly led to the establishment of more rigorous drug approval processes and the creation of formal spontaneous reporting systems, beginning with the "Yellow Card Scheme" in the UK in 1964 and inspiring similar systems globally.

More recent history continues to demonstrate the critical importance of vigilant post-marketing surveillance. The voluntary withdrawal of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx) in 2004 is a classic case study. After being used by an estimated 80 million patients, post-marketing studies revealed a significant increase in the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke [18]. It was estimated that rofecoxib may have contributed to over 88,000 heart attacks in the U.S. alone during its five years on the market. This event highlighted the limitations of pre-marketing trials in detecting risks that are context-specific, such as those affecting patients with underlying cardiovascular risk factors, and underscored the vital role of post-approval studies and spontaneous reports in identifying such "signals."

In response to these challenges and tragedies, the scope of pharmacovigilance has expanded significantly. The World Health Organization (WHO) defines its objectives as aiming to improve patient care and safety in relation to the use of medicines, and to support public health programs by providing reliable information for the effective assessment of the risk-benefit profile of drugs [19]. This involves not just the passive collection of spontaneous reports but also active surveillance methods, such as utilizing electronic health records and large administrative databases to proactively search for safety signals. The ultimate goal is to translate this information into effective risk minimization measures, which can range from updating product labeling with new warnings and contraindications, to communicating directly with healthcare professionals, or, in the most serious cases, restricting a drug's use or removing it from the market entirely [20].

3. Evolution of the Pharmacist's Role in Patient Safety

The catalysts for this paradigm shift are multifaceted. The advent of mass-produced, pre-packaged pharmaceuticals by the mid-20th century largely eliminated the need for extemporaneous compounding as the pharmacist's primary duty. This technological liberation created the capacity for a new professional focus. Concurrently, the increasing complexity of the pharmaceutical arsenal, the rise of polypharmacy—particularly among aging populations—and the stark revelations of drug safety disasters like the thalidomide tragedy, collectively highlighted a critical gap in the healthcare system. There was a clear and urgent need for a professional whose expertise was dedicated to the entire medication use process, not just its supply. This led to the formal adoption of a new philosophy known as "pharmaceutical care," a term codified by Hepler and Strand in 1990, which they defined as "the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life" [21]. This model explicitly charges pharmacists with identifying, resolving, and preventing drug therapy problems, thereby establishing a direct link between their practice and the core objectives of pharmacovigilance.

This philosophical shift was operationalized through significant changes in pharmacy education and practice standards. University curricula evolved from a heavy emphasis on chemistry and pharmaceutics to a robust integration of clinical sciences, including pharmacology, pharmacotherapy, pathophysiology, and patient assessment. The widespread adoption of the Doctor of Pharmacy (Pharm.D.) as the sole professional entry-level degree in the United States and its increasing adoption globally cemented this clinical orientation, producing graduates trained to make evidence-based decisions in complex patient scenarios [22]. In parallel, the scope of practice for pharmacists has been legally and professionally expanded in many countries. Key advancements include the authority to administer vaccinations, conduct comprehensive medication reviews, order and interpret laboratory tests related to drug therapy, and in some jurisdictions, even prescribe medications for specific conditions or manage therapy under collaborative practice agreements [23]. These expanded responsibilities have moved pharmacists from the periphery to the center of patient care teams.

The strategic positioning of pharmacists within the healthcare system makes them uniquely effective as pharmacovigilance sentinels. In the community

setting, pharmacists are among the most accessible healthcare professionals, often seeing patients without the need for an appointment. This accessibility creates repeated touchpoints where pharmacists can monitor for potential ADRs. A patient may visit a physician for a diagnosis and initial prescription, but they often return to the pharmacy multiple times for refills, advice on over-the-counter products, or to discuss minor health concerns. It is during these subsequent interactions that a pharmacist may be the first to connect a new symptom to a recently initiated or chronic medication—a connection that might be missed in a once-yearly physician check-up. Studies have shown that community pharmacists can effectively identify and report a significant number of previously unknown ADRs, particularly those affecting quality of life that patients may not deem serious enough to report to a physician [24].

In the hospital environment, the integration of clinical pharmacists into multidisciplinary rounds has been a game-changer for patient safety. These pharmacists have direct access to patient charts, laboratory data, and the treating medical team, allowing for real-time intervention. They are trained to identify signals such as a rising serum creatinine level in a patient on renally-excreted drugs, a sudden drop in platelets in a patient on heparin, or a new electrolyte imbalance potentially linked to a diuretic. Their systematic approach to reviewing medication profiles for drug-drug interactions, duplications, and inappropriate dosing acts as a proactive form of pharmacovigilance, preventing ADRs before they occur. Research has consistently demonstrated that the presence of clinical pharmacists on patient care teams leads to a significant reduction in preventable ADRs and medication errors [25].

The concept of "medication reconciliation," now a standard of care in hospitals worldwide, further exemplifies this evolved role. This process, which involves creating the most accurate list possible of all medications a patient is taking and comparing it to the physician's admission, transfer, and discharge orders, is ideally suited to pharmacist expertise. It is during reconciliation that discrepancies—such as omitted medications, incorrect doses, or undocumented drug allergies—are identified and corrected. These discrepancies are a common source of medication errors and subsequent ADRs, and pharmacist-led reconciliation has been proven to dramatically reduce these errors at care transitions, a known high-risk period for patients [26].

The COVID-19 pandemic served as a powerful, real-time validation of this evolved role. Pharmacists were thrust into the forefront of public health, not only by ensuring the integrity of the drug supply chain but also by becoming primary administrators of vaccines and providers of point-of-care testing. In this capacity, they were on the front lines of monitoring and reporting adverse events following immunization for novel COVID-19 vaccines. Their direct interaction with millions of patients provided an unprecedented volume of real-world safety data, which was critical for regulatory agencies to confirm the safety profile of these new biological products and to identify very rare events like thrombosis with thrombocytopenia syndrome (TTS) associated with viral vector vaccines [27]. The pandemic unequivocally demonstrated that pharmacists are not just ancillary staff but essential contributors to national and global public health security.

4. Pharmacists in Community and Ambulatory Care Settings

The process of medication dispensing, often perceived as a simple transactional task, is in fact a critical first line of defense. Before a medication is handed to a patient, the pharmacist conducts a prospective drug utilization review (DUR). This involves a systematic analysis of the prescription against the patient's profile to identify potential problems, including drug-drug interactions, drug-disease contraindications, inappropriate dosages, and therapeutic duplication. Computerized clinical screening systems provide alerts, but it is the pharmacist's clinical judgment that assesses the relevance and severity of these alerts. For instance, while an automated system might flag a potential interaction between two medications, the pharmacist evaluates the clinical significance, considers the patient's specific context, and decides whether to dispense the medication with counselling, contact the prescriber for an alternative, or manage the risk through monitoring. This proactive review prevents many potential ADRs from ever occurring and represents a form of pre-emptive pharmacovigilance [32].

Perhaps the most significant opportunity for ADR detection lies in patient counselling. This mandatory or voluntary interaction at the point of dispensing is a pivotal moment for pharmacovigilance. When providing counselling on a new medication, a pharmacist does not merely explain how to take it; they also describe potential side effects, empowering the patient to recognize and report them. More importantly, when a patient returns for a refill or seeks advice for a new symptom, the pharmacist is ideally placed to inquire about any new health developments since starting the medication. A patient might mention in

passing, "Oh, I've been feeling a bit dizzy since I started these new blood pressure pills," or "This new antibiotic seems to be upsetting my stomach." To a physician, this might be an unrelated complaint during a busy appointment; to a pharmacist, it is a potential ADR signal. This "therapeutic questioning" is a skilled activity that transforms a routine refill into a valuable safety monitoring session [33].

Beyond the dispensing counter, pharmacists engage in more structured clinical services that are rich with pharmacovigilance opportunities. Medication Therapy Management (MTM) is a comprehensive service offered to patients, particularly those with multiple chronic conditions and complex medication regimens. During a structured MTM session, the pharmacist conducts a full review of all medications—prescription, over-the-counter, and herbal supplements—assesses the patient's understanding and adherence, and identifies any possible drug therapy problems, including ADRs. Studies have shown that pharmacist-led MTM services significantly improve medication adherence and patient outcomes while simultaneously identifying and resolving a high number of medication-related problems, including previously unreported adverse effects [34]. This formalized, in-depth review often uncovers chronic, low-grade ADRs that patients have accepted as a normal part of life or aging, such as persistent dry mouth from an antidepressant or fatigue from a beta-blocker.

The management of over-the-counter (OTC) medications and herbal products represents another critical frontier. Patients often do not consider these products to be "drugs" and therefore rarely report their use to physicians or associate them with adverse effects. A community pharmacist, however, is often consulted for self-care advice. In this role, they can screen for potential interactions between a requested OTC product and the patient's existing prescription regimen. For example, they can caution a patient on warfarin against taking aspirin or certain herbal supplements like ginkgo biloba, thereby preventing a serious bleeding event. Furthermore, when a patient presents with symptoms that could be either an illness or an ADR, the pharmacist's triage and questioning can help differentiate the cause. A patient complaining of a persistent cough, for instance, might be experiencing a known side effect of their ACE inhibitor rather than a respiratory infection [35].

The growing integration of ambulatory care pharmacists within primary care clinics has further solidified this frontline role. These embedded pharmacists work collaboratively with physicians to manage chronic diseases such as diabetes, hypertension, and heart failure. In this capacity, they perform routine follow-up, titrate medications according to protocols, and monitor for both efficacy and toxicity. For a patient on a statin, the ambulatory care pharmacist ensures liver function tests are monitored; for a patient on methotrexate, they track complete blood counts. This systematic, protocol-driven monitoring is a powerful form of active pharmacovigilance that catches ADRs early, often before they become symptomatic or severe [36]. Their detailed documentation in shared electronic health records ensures that these potential ADRs are communicated to the entire care team.

Despite this ideal positioning, several challenges persist in community-based pharmacovigilance. A significant barrier is the lack of formalized time and remuneration for cognitive services like ADR monitoring and reporting. The pharmacy's business model is often still driven by dispensing volume, leaving little time for in-depth patient consultations. Furthermore, a phenomenon known as "the checklist mentality" can occur, where the focus is on completing the technical tasks of dispensing rather than engaging in clinical surveillance [37]. There is also a common misconception among both patients and some healthcare professionals that only severe or unusual ADRs should be reported, leading to under-reporting of common or non-serious reactions that are nonetheless impactful on a patient's quality of life.

5. Hospital and Clinical Pharmacists in ADR Detection and Management

The integration of clinical pharmacists into multidisciplinary ward rounds represents a cornerstone of modern hospital pharmacovigilance. This practice moves pharmacy expertise from the basement dispensary to the patient's bedside, enabling real-time, pre-emptive intervention. During these rounds, the pharmacist reviews medication orders as they are written, providing immediate consultation on drug selection, dosing, and monitoring. For example, when a physician prescribes vancomycin for a patient with deteriorating renal function, the clinical pharmacist can immediately recommend a dose adjustment based on the patient's latest creatinine clearance and suggest monitoring vancomycin trough levels. This proactive intervention prevents toxic levels from accumulating, thereby averting a potential ADR like nephrotoxicity or ototoxicity before it can manifest [41]. Their presence ensures that the right patient receives the right drug at the right dose at the right time, fundamentally altering the safety profile of inpatient medication use.

A critical and formalized process where hospital pharmacists excel is medication reconciliation. This structured review is performed at all transitions of care: admission, transfer between units, and discharge. It involves creating a complete and accurate list of a patient's pre-admission medications and comparing it to the current inpatient orders. Discrepancies are extremely common and are a prolific source of medication errors that can lead to ADRs. An unintentional omission of a chronic beta-blocker can lead to rebound tachycardia and hypertension; the failure to restart an anticonvulsant can result in a seizure. Pharmacist-led medication reconciliation has been proven to be highly effective in identifying and rectifying these unintentional discrepancies. A systematic review and meta-analysis by Mekonnen et al. concluded that pharmacist-led reconciliation interventions at hospital transitions were associated with a significant reduction in medication discrepancies and potential ADRs [42]. By ensuring continuity and accuracy of the medication record, pharmacists close a major safety gap in the patient care pathway.

Hospital pharmacists also lead and participate in targeted quality improvement and safety programs that constitute a form of active, systematic pharmacovigilance. A prime example is Antimicrobial Stewardship Programs (ASPs), where pharmacists work with infectious disease specialists to promote the appropriate use of antibiotics. In this role, they monitor for ADRs associated with antimicrobials, such as *Clostridioides difficile* infection following broad-spectrum antibiotic use, nephrotoxicity from aminoglycosides, or hematological toxicity from linezolid. They review culture results and de-escalate therapy when possible, directly reducing the risk of ADRs without compromising clinical outcomes [43]. Similarly, pharmacists often manage protocols for high-risk medications like anticoagulants (e.g., warfarin, heparin) and chemotherapeutic agents. They dose, monitor, and adjust these therapies based on laboratory parameters and clinical response, systematically preventing adverse events like bleeding episodes or severe myelosuppression [44].

When an ADR does occur, the hospital pharmacist is a key figure in its management and analysis. They are frequently called upon to assist in causality assessment, using structured algorithms like the Naranjo scale to determine the likelihood that a drug caused a specific adverse event [45]. This professional judgment adds a layer of objectivity and pharmacological expertise to the process. Furthermore, they play a crucial role in managing the ADR once it is identified. This may involve recommending specific antidotes (e.g., naloxone for opioid overdose, flumazenil for benzodiazepine overdose), suggesting alternative medications, and providing supportive care recommendations. Their involvement ensures that the clinical team's response is pharmacologically sound and evidence-based.

Beyond direct patient care, hospital pharmacists contribute to pharmacovigilance at an institutional level through the Pharmacy and Therapeutics (P&T) Committee. This multidisciplinary committee is responsible for formulating the hospital's drug policy, including the drug formulary. Pharmacists provide critical safety analyses of new drugs being considered for inclusion, reviewing post-marketing surveillance data and comparing the ADR profiles of new agents to existing ones. They also help develop and implement clinical guidelines and protocols that incorporate safety measures, such as mandatory monitoring requirements or restricted use for drugs with a narrow therapeutic index [46]. In this capacity, they are shaping the very system in which medications are used to proactively minimize risk for the entire patient population.

The hospital pharmacy's Drug Information Service (DIS) acts as a central pharmacovigilance resource for the entire institution. When a healthcare professional encounters a potential ADR or has a question about a drug's safety profile, they often consult the DIS. The pharmacists staffing this service perform detailed literature searches, analyze case reports, and provide evidence-based answers that guide clinical decision-making. They are also typically responsible for coordinating the institution's internal ADR reporting program, educating staff on reporting procedures, and collating and submitting reports to the national regulatory authority [47]. This centralization of expertise makes the DIS a vital hub for drug safety knowledge and activity within the hospital.

6. Conclusion

This research has systematically examined the pivotal and multi-faceted role of pharmacists in the domain of pharmacovigilance and adverse drug reaction (ADR) reporting. The evidence presented leads to an unequivocal conclusion: pharmacists have evolved from their traditional role as dispensers of medicines to become indispensable sentinels and clinical gatekeepers in the medication safety ecosystem. Their unique position at the interface between patients, physicians, and the complex world of pharmaceuticals empowers them to be proactive agents in detecting, assessing, understanding, and preventing adverse drug events.

The analysis began by establishing the critical need for robust post-marketing surveillance, highlighting the inherent limitations of pre-approval clinical trials and the significant public health and economic burden posed by ADRs. It then traced the professional evolution of pharmacists, demonstrating how their expanded clinical training and patient-centered philosophy have prepared them for this vital safety role. The investigation detailed their frontline activities in community and ambulatory care settings, where medication reviews, patient counselling, and management of over-the-counter products serve as continuous mechanisms for ADR detection. Furthermore, it illuminated their profound impact within hospital walls, where their integration into multidisciplinary teams, leadership in medication reconciliation, and stewardship of high-risk medications systematically prevent patient harm.

The journey through this analysis confirms that the pharmacist's contribution is not merely additive but transformative to pharmacovigilance systems. They bridge a critical gap left by the pervasive under-reporting that plagues spontaneous reporting systems. Their clinical expertise allows them to perform crucial causality assessments, and their accessibility provides a longitudinal view of a drug's effects in the real world, far beyond the controlled confines of a clinical trial. The COVID-19 pandemic served as a powerful testament to this, where pharmacists globally were instrumental in administering novel vaccines and monitoring their safety in real-time, providing invaluable data to regulatory bodies and the public.

Therefore, the findings of this research compel a call to action. To fully leverage the potential of pharmacists in pharmacovigilance, systemic barriers—such as lack of time, insufficient training in reporting procedures, and inadequate integration into healthcare workflows—must be addressed. Healthcare systems and policymakers must work to formally integrate pharmacovigilance activities into the standard of care provided by pharmacists, supported by appropriate remuneration, streamlined reporting technology, and inter-professional collaboration. Enhancing pharmacovigilance education in undergraduate and postgraduate pharmacy curricula is equally crucial.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

[1] Yu YM, Lee E, Koo BS, et al. Predictive factors of spontaneous reporting of adverse drug reactions among community pharmacists. PLoS One. 2016;11(5):e0155517.

[2] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200-1205.

[3] Glassman P. Clinical pharmacist's role in preventing adverse drug events: brief update review. In: Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices. Rockville, MD: Agency for Healthcare Research and Quality; 2013.

[4] Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernández-Benítez M, Fernández LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Ann Pharmacother. 2008;42(10):1491-1496.

[5] Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-19.

[6] van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13(7):457-464.

[7] Duarte M, Ferreira P, Soares M, Cavaco A, Martins AP. Community pharmacists' attitudes towards adverse drug reaction reporting and their knowledge of the new pharmacovigilance legislation in the southern region of Portugal: a mixed methods study. Drugs Ther Perspect. 2015;31(9):316-322.

[8] Mann R, Elizabeth A. Pharmacovigilance. 2nd ed. West Sussex, England: John Wiley & Sons Ltd; 2007.

[9] Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437-453.

[10] Calvert RT. Clinical pharmacy—a hospital perspective. Br J Clin Pharmacol. 1999;47(3):231-238.
[11] Saygi S, Alkas FB, Etikan I, Gelisen I, Sardas S. Pharmacovigilance awareness among the community pharmacists and pharmacy students in the Turkish Republic of Northern Cyprus. J Pharmacovigil. 2016;4:204.
[12] Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol. 2001;51(1):81-86.
[13] Olsson S. National Pharmacovigilance Systems-Country profiles and Overview. 2nd ed. Uppsala: Uppsala Monitoring Centre; 1999.
[14] Abdel-Latif MMM, Abdel-Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among health-care professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharm J. 2015;23(2):154-161.
[15] World Health Organization. International drug monitoring: the role of national centres. Report of a WHO Meeting. Geneva: 1972.
[16] Jose J, Jimmy B, Al-Ghailani ASH, Al-Majali MA. A cross sectional pilot study on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related aspects in the Sultanate of Oman. Saudi Pharm J. 2014;22(2):163-169.
[17] Hadi MA, Ming LC. Impact of pharmacist recruitment on ADR reporting: Malaysian experience. South Med Rev. 2011;4(2):102-103.
[18] Lynn RM, Riding K, McIntosh N. The use of electronic reporting to aid surveillance of ADRs in children: a proof of concept study. Arch Dis Child. 2010;95(4):262-265.
[19] Rossi AC, Knapp DE, Anello C, et al. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA. 1983;249(16):2226-2228.
[20] Schlienger RG, Lüscher TF, Haefeli WE, Schoenenberger RA. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci. 1999;21(3):110-115.
[21] Obara T, Yamaguchi T, Satoh M, et al. Prevalence, determinants and reasons for the non-reporting of adverse drug reactions by pharmacists in the Miyagi and Hokkaido regions of Japan. Adv Pharmacoepidemiol Drug Saf. 2015;4:191.
[22] Suyagh M, Farah D, Abu-Farha R. Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J. 2015;23(2):147-153.
[23] Green CF, Mottram DR, Rowe P, Brown AM. Attitudes of hospital pharmacists to adverse drug reaction reporting: a qualitative survey. Int J Pharmacy Prac. 1999;7(4):247-255.
[24] Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
[25] Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75-81.
[26] Elkalmi RM, Hassali MA, Ibrahim MI, Jamshed SQ, Al-Lela OQ. Community pharmacists' attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: an quantitative insight. J Patient Saf. 2014;10(2):81-87.
[27] Khan TM. Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Ther Adv Drug Saf. 2013;4(2):45-51.
[28] Gavaza P, Bui B, Candidate P. Pharmacy students' attitudes toward reporting serious adverse drug events. Am J Pharm Educ. 2012;76(10):1-6.
[29] Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf. 2000;23(2):165-172.
[30] Pagotto C, Varallo FR, Mastroianni PC. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410-417.
[31] Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317-328.
[32] Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25(8):1289-1297.
[33] Mahmoud MA, Alswaida Y, Alshammari T, et al. Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J. 2014;22(5):411-418.
[34] Roberts PI, Wolfson DJ, Booth TG. The role of pharmacists in adverse drug reaction reporting. Drug Saf. 1994;11:7-11.
[35] Al-hazmi NN, Naylor IL. A study of community pharmacists' awareness and contributions to adverse drug reactions (ADRs) reporting systems in the Makkah, Kingdom of Saudi Arabia. J Clin Trials. 2013;3:127.
[36] Osemene KP, Ayeni MI, Afolabi MO. The role of community pharmacists in monitoring adverse drug reactions in Nigeria. J Pharm Health Serv Res. 2012;3(4):197-204.
[37] Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance – lack of vigilance, lack of trust. JAMA. 2004;292(21):2647-2650.
[38] Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. J Pharm Health Serv Res. 2013;4:155-158.
[39] Rajiah K, Maharajan MK, Nair S. Pharmacy students' knowledge and perceptions about adverse drug reactions reporting and pharmacovigilance. Saudi Pharm J. 2016;24(5):600-604.

[40] Liu J, Zhou Z, Yang S, et al. Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. Int J Clin Pharm. 2015;37(3):457-464.

[41] Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions? CMAJ. 2006;174(2):191-192.

[42] Qassim S, Metwaly Z, Shamsain M, Al-Hariri Y. Reporting adverse drug reactions: evaluation of knowledge, attitude and practice among community pharmacists in UAE. IOSR J Pharm. 2014;4:17-23.

[43] Rabba AK, Mohammad R. Pharmacovigilance Study: Exploring the Role of Community Pharmacists in Adverse Drug Reactions Reporting in Alkharj City, Saudi Arabia. Lat Am J Pharm. 2015;34(5):901-906.

[44] Elkalmi RM, Hassali MA, Ibrahim MI, Widodo RT, Efan QM, Hadi MA. Pharmacy students' knowledge and perceptions about pharmacovigilance in Malaysian public universities. Am J Pharm Educ. 2011;75(5):96.

[45] Farha RA, Alsous M, Elayeh E, Hattab D. A cross-sectional study on knowledge and perceptions of pharmacovigilance among pharmacy students of selected tertiary institutions in Jordan. Tropical J Pharm Res. 2015;14:1899-1905.

[46] Isfahani ME, Mousavi S, Rakhshan A, Assarian M, Kuti L, Eslami K. Adverse drug reactions: knowledge, attitude and practice of pharmacy students. J Pharm Care. 2013;1:145-148.

[47] Ahmad A, Khan MU, Moorthy J, Kumar BD, Kumar GS, Patel I. Comparison of knowledge, attitudes and perceived barriers towards adverse drug reactions reporting between bachelor of pharmacy and doctor of pharmacy students in southern India. J Pharma Health Serv Res. 2016;7:63-69.